KRAS and familial pancreatic carcinoma: In keeping with this observation KRAS mutations have been found by several studies to be associated with increased VTE risk across a spectrum of human malignancies, namely in colorectal (36, 66), lung (36, 67, 75), and pancreatic cancers (36, 76).